侵袭性黑色素瘤肿瘤升期与临床管理改变及更差预后相关
一项基于2014-2018年州级SEER附属癌症登记处的回顾性研究纳入4391例侵袭性黑色素瘤,发现9.4%发生肿瘤升期;升期导致超过一半病例临床管理改变,但仅37.4%完成额外治疗推荐;升期者总体死亡率和黑色素瘤特异性死亡率均显著更高。
要点
- 侵袭性黑色素瘤中肿瘤升期发生率为9.4%。
- 升期者总体死亡率和黑色素瘤特异性死亡率显著更高。
- 升期后仅37.4%病例完成额外治疗推荐。
核心结论
- 侵袭性黑色素瘤肿瘤升期与更差的生存结局相关,可能源于临床管理的不足。
研究设计与样本
- 回顾性研究,使用2014至2018年州级SEER附属癌症登记处数据,纳入4391例侵袭性黑色素瘤病例。
主要发现
- 4391例侵袭性黑色素瘤中9.4%发生肿瘤升期。
- 单因素分析中显著风险因素包括年龄较大、男性、非白种人、头颈部位置、较大临床尺寸、切开和/或钻取活检方法及活检与手术切除间时间增加。
- 多因素分析中显著风险因素包括头颈部位置和更高病理T分期。
- 肿瘤升期在超过一半病例中决定了临床管理改变,但仅37.4%符合额外治疗推荐。
- 升期黑色素瘤相比未升期者总体死亡率更高(36.0% vs 19.5%;P < .001),黑色素瘤特异性死亡率更高(9.0% vs 2.9%;P < .001)。
临床怎么用
- 对侵袭性黑色素瘤应关注肿瘤升期风险,尤其是头颈部位置和更高病理T分期者。
- 升期后需确保临床管理改变落实,提高额外治疗推荐的完成率。
局限性
- 单中心回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical implications and prognostic outcomes associated with tumor upstaging in invasive melanoma have not been well established. OBJECTIVES: To determine the frequency of tumor upstaging in invasive melanoma, identify risk factors, and assess its impact on clinical management and outcomes. METHODS: A retrospective study using data from a statewide Surveillance Endpoints and End Results-affiliated cancer registry between 2014 and 2018 was performed. Multivariable hazard models were used to determine factors associated with upstaging and overall/melanoma-specific mortality. RESULTS: Of 4391 cases of invasive melanoma, 9.4% were upstaged. Significant risk factors on univariate analysis included older age, male sex, non-White race, head/neck location, larger clinical size, incisional and/or punch biopsy method, and increasing time between biopsy and surgical excision. Significant risk factors on multivariable analysis included head/neck location and higher pathologic T stage. Tumor upstaging dictated a change in clinical management in over half of cases; however, only 37.4% fulfilled the recommendation for additional treatment. Upstaged melanomas experienced higher overall (36.0% versus 19.5%; P < .001) and melanoma-specific (9.0% versus 2.9%; P < .001) mortality compared to non-upstaged tumors. LIMITATIONS: Single-center retrospective study. CONCLUSIONS: Tumor upstaging in invasive melanoma is associated with worse survival outcomes, possibly due to shortfalls in clinical management.
引用
- Rosenthal A, Kim JY, Juhasz MLW, et al. Tumor upstaging in invasive melanoma is associated with changes in clinical management and worse prognosis. J Am Acad Dermatol. 2024. PMID: 39579989. doi:10.1016/j.jaad.2024.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。